Global Wellness Strategies Inc. and their contract research organization (CRO) iNGENü signed supply agreement with PharmAla Biotech to supply GMP MDMA for the shanti therapeutics upcoming clinical trial. Global Wellness' Shanti Therapeutics is a first-in-class biotech utilizing the neuromodulation properties of MDMA (aka Ecstasy) to pre-emptively treat preoperative pain. Shanti has commenced a path to their clinical trial in 2022 healthy volunteers comparing the pain tolerance threshold in patients had exposure to a proprietary dose and formulation of MDMA.

This proof-of-concept clinical study is to gauge the effect size of an increase in the pain threshold in subjects to pre-emptively treated with MDMA. iNGENü was chosen as the contract research organization (CRO), as they are a niche CRO specialized in novel psychedelic clinical trials.